Purpose: To develop a method for data-driven exploration in pharmacovigilance and illustrate its use by identifying the key features of individual case safety reports related to medication errors.
depth with the aim of understanding the reporting patterns and of identifying patients at risk. This is growing in importance as the number of contributed reports in many regions has increased substantially in the past 10 years. Similar analyses may also address questions related to data management ("are some ADR terms coded to more often in one region than in others?") or provide context and points of reference for subsequent signal detection or exploration ("what are the differences between reports for children and adults, in general?").
A natural first step is to obtain basic descriptive statistics and data visualization. Domain experts familiar with a data source of interest can sometimes directly spot unexpected and important features of a data set from descriptive overviews: a simple example would be an overrepresented age group in reports from a certain country compared with the database as a whole. Often, such analyses are performed ad hoc with restricted scope determined by domain experts, because broad, openended analyses are challenging to scrutinize. Moreover, manual review may be tedious, yield inconsistent results, and be difficult to reproduce.
Computational identification of key features within large and complex data sets would speed up exploratory analysis, ideally while ensuring transparency and reproducibility. In this context, key success factors are analytics that incorporate and support domain expert interpretation.
Individual case reports do not derive from experimental settings, and their collection is not devised to minimize bias and heterogeneity. Complex analytical methods whose output cannot easily be traced back to the underlying data are of little value and potentially harmful, especially considering data quality deficiencies and systematic biases that may undermine correct inference. Simpler analyses on the other hand need to be interpreted with caution because they typically do not account for the influence of other covariates than those of primary interest.
We propose vigiPoint, a simple but versatile method for data exploration that outlines data subsets of interest, pinpoints their key features, and facilitates expert review. It utilizes odds ratios with adaptive statistical shrinkage to balance absolute frequency and strength of association in a single measure of relevance. 9 Individual analyses are univariate, considering one covariate at a time, which places them at the lower end of methodological sophistication, but at the higher end of transparency and robustness to random variability and data quality distortions. We illustrate the use of vigiPoint through a case study of highlighting key features of the 164 000 medication error reports among 8 million reports in the WHO global individual case safety reports database, VigiBase, 10 up until May 31, 2013.
2 | METHODS
| vigiPoint
We describe vigiPoint, a method for highlighting key features of subsets of data. In this context, a feature can be a specific value (or set of values) of a discrete covariate (eg, country of origin = Tunisia) or a range of values for a numerical covariate (eg, patient age is greater than or equal to 2 years and less than 12 years). It compares a data subset of interest to one or more comparator data sets and identifies substantial differences in the relative frequencies of their respective
features. This requires focus on relative differences of great enough magnitude while suppressing highly local patterns. Domain experts and data scientists define subsets of interest, comparators, and features to be analysed, whereas vigiPoint provides a generic analysis method independent of the user-defined scope. The guiding principles for vigiPoint are described in Table 1 .
| Scope
Key design choices for each individual analysis include the subset of interest, the comparator(s), the covariates, and corresponding features for analysis, as illustrated in Figure 1 . The subset of interest should encompass the data of focus for the analysis. For one-off analyses, this may be any collection of data, but subset definitions based on covariate criteria (for example all records from a given time period or demographic category) ensure reproducibility and facilitate definition of the comparator. An outline for the principles that we employ when defining comparators is provided in Figure 1 . To identify key features, the relative frequency of covariate values in the subset of interest is contrasted to those in a comparator data set. The comparator is typically another subset of the same data. In our descriptions below, it is assumed not to include the subset of interest. Several comparators may be used in parallel, in which case only covariate values whose frequencies deviate significantly from those in each comparator will be highlighted.
KEY POINTS
• 
Describe broad features
Highlight broad features of the data subset of interest, and suppress highly local patterns that affect very small proportions of the subset.
Pinpoint the difference
Highlight features that are substantially more common or substantially rarer in the subset of interest than in the comparator. Focus on relative differences, but ensure applicability for overall common as well as for overall rare covariate values.
Facilitate expert review
Support expert manual review by providing a transparent trace to the empirical basis for any highlighted feature, so that the corresponding individual records can be reviewed for relevance.
Balance structure with flexibility
Rely on experts to define subsets of interest, comparators, and covariates to be analysed, but provide a generic method for analysis independent of the user-defined scope.
| Shrinkage odds ratios
vigiPoint builds on earlier work where observed-to-expected ratios are used to identify patterns based on strength of association. 9 In vigiPoint, key features are identified using odds ratios subjected to statistical shrinkage. Odds ratios have the advantage over other measures of association such as mutual information, relative risk (including Proportional
Reporting Ratios and Information Component values), and cosine similarity, 11 of working well for common as well as for rare covariates. As an example, the log odds ratio for 99% vs 90% has the same absolute value as that for 1% vs 10%, which makes sense because they might describe complementary events (eg, reports from Canada vs reports from other countries than Canada), and in that sense, reflect the same association.
As vigiPoint focuses on relative frequencies, numerical covariates must be grouped into categories prior to analysis. A key consideration here is granularity: finer categories may enable more specific findings but may also make results difficult to survey and lead to loss of statistical power.
An effective compromise may be to display results of finer granularity grouped in broader categories (eg, analysis by years grouped by decades). ratio for the occurrence of x in the subset of interest can be estimated from the contingency table as:
We may rearrange this ratio and view O=a as the observed count and E=bc/d as the expected count:
To protect against spurious associations and to restrict focus to features with strong enough associations and prevalence in the case series, we apply statistical shrinkage to the odds ratio through addition of a constant k to both the observed and the expected counts:
The shrinkage moderates the odds ratio towards its baseline value of 1, and the log OR towards 0. The moderation is more prominent for smaller observed or expected counts (less than or of the same magnitude as k). As the observed and expected counts increase, the shrinkage odds ratio converges to the raw odds ratio.
With the above transformation, the shrinkage odds ratio corresponds to the Bayesian posterior mean of an intensity parameter μ for a Poisson Po(μ · E)-distributed O with a Gamma prior distribution for μ: G(k; k). The corresponding posterior distribution for μ is also Gamma (but with parameters O + k and E + k). Credibility intervals that indicate a range of values of μ compatible with data can be calculated by the inverse of the Gamma cumulative distribution function. 9 
| Adaptive shrinkage
The Information Component measure of disproportionality is based on a similar shrinkage observed-to-expected ratio but uses a strength of shrinkage corresponding to k = 0.5. 9 This is appropriate in the context of ADR surveillance which must be sensitive to rare patterns. The primary focus of vigiPoint on the other hand is to highlight broad patterns that involve a substantial proportion of the subset of interest.
For this reason, we use a stronger shrinkage and adapt the strength of the shrinkage to the size of the subset of interest. In our baseline implementation used here, shrinkage is set to k = 0.01 · N, where N denotes the size of the subset of interest (except we do not allow k to fall below 0.5, to ensure adequate shrinkage for smaller subsets).
| Threshold for key features
To protect against chance findings, we use percentiles of a two-sided
Bayesian credibility interval for the shrinkage odds ratio as our basis for pattern discovery rather than the central estimate. The width of the credibility interval is determined by permutation analysis, as described later. As default, we use a 99% two-sided Bayesian credibility interval.
Strength of association is measured and presented as the logarithm of the shrinkage odds ratio so that absolute values reflect the strength of association on a common scale regardless of the association direction.
In order to only highlight features that deviate substantially from the expected, the threshold for the credibility interval of the log odds ratio is set to 0.5 and −0.5, respectively. This corresponds to just over a 40%
over-representation or under-representation in the subset of interest in relation to the comparator, thus ensuring that highlighted features are not only statistically significant but relevant also from a practical perspective. Figure 1 illustrates how features are highlighted based on the value of the lower or upper limit of the credibility interval.
| Nested analysis
vigiPoint outlines a subset of interest and pinpoints its key features.
Often, there will be an interest in following up some of the highlighted key features by nested vigiPoint analysis for a specific subset. These nested analyses would typically be specified by the analyst based on their domain expertise and aim of analysis. Automated nested analysis through recursive application of vigiPoint to subsets defined by highlighted co-variate values in a primary vigiPoint analysis is also possible and an interesting area for future research.
| Permutation analysis
Chance findings are a real concern when executing large numbers of multiple comparisons in parallel. 12 To protect against spurious associations from random variability, vigiPoint utilizes statistical shrinkage and Bayesian credibility intervals. Still, its vulnerability to chance findings will vary with the number and granularity of covariates, and their correlation.
As a general method to assess this for a specific vigiPoint analysis, we propose a permutation analysis, where subset membership is scrambled, but the size of each subset is intact. We then apply vigiPoint for the same range of covariates. Given the random allocation of reports to the subset of interest and the comparator, any highlighted feature in the permutation analysis is spurious. The proportion of spurious associations can thus be estimated as the number of highlighted features in the permutation analysis compared with that in the original analysis.
2.8 | Case study
VigiBase is the world 0 s largest repository of individual case safety reports. 10 These are reports of suspected harm from medicines from For the case study, we defined the subset of interest as reports with at least one medication error related term defined with the MedDRA® High Level Group Term "Medication errors", except for the subordinated Preferred Terms "Intentional overdose" and "Overdose". As comparator, we used all other reports in VigiBase.
| Scope of analysis for case study
The covariates included in the analysis were year of report entry into There were medication error reports for all age groups but higher proportions of reports on 2 to 11 year olds (10% vs 5.7% on reports of other adverse events, Figure 5 ) and without age specified (Figure 4 ).
The gender distribution was the same for medication error reports as for other reports in VigiBase (M = 39%, F = 61%), but gender was more often missing on medication error reports: 12% vs 6.4% for other reports in VigiBase (Figure 4 ).
Greater than expected reporting rates of medication errors were found for drugs used for respiratory and nervous systems disorders, as well as drugs used for alimentary tract and metabolism disorders (eg, drugs used for gastro-oesophageal reflux, propulsives, and insulins). A number of MedDRA High-Level Terms found in the MedDRA system organ classes "Social circumstances," "Surgical and 
| Nested analysis results

| Permutation analysis results
The permutation analysis for the primary and nested vigiPoint analyses did not highlight any key features at the suggested thresholds, OR 005 > 0.5 or OR 995 < −0.5. This can be compared with 109 key features highlighted in the primary analysis for the case study, which suggests that the expected proportion of chance findings in our analysis is very low.
| DISCUSSION
vigiPoint provides a method to quickly highlight key features that distinguish a data subset of interest from one or more comparators.
In our case study, it identified the large proportions of medication error reports that come from the United States and from patients, but also drew to light subtler patterns such as the over-representation to over fit to peculiarities of the data set at hand, and so less vulnerable paradox, 13 where it would be incorrect to infer that patients are more likely than others to report medication error. In reality, medication errors were more common on direct patient reports than on other reports for each of the 5 countries in our nested analysis.
An additional challenge with univariate analyses is that they do not encompass higher order associations. There may for example be countries with high rates of medication error reports from physicians, even though the overall rate of medication error reports from physicians is low. This can to some extent be handled by nested vigiPoint analyses: in our study, such patterns would have been highlighted for the 5 countries analysed in closer detail, but not for any of the other countries.
Our use of univariate analysis over regression for primary analyses in vigiPoint derives from the ambition to first describe and then interpret, and for vigiPoint to serve as a guide rather than a final answer when screening for data patterns. This transparency also makes it easier to detect data quality issues and implementation errors, because unexpected patterns cannot be attributed to sophisticated
analytics. An interesting area of future research is to explore whether to obtain because subjective judgement is fraught with inter-rater and intra-rater variability. However, the permutation analysis integral to vigiPoint ensures that highlighted patterns most likely reflect real differences and not random fluctuations, which is an important first step. Of course, these patterns reflect variations in data and not necessarily in the underlying population: our case study has highlighted differences in the reporting of medication errors that may not reflect variations in its occurrence. As always, it is important to bear in mind the nature of the underlying data, in drawing conclusions based on the analysis.
As regards the relevance to domain experts, vigiPoint (or earlier incarnations thereof) has been used and found valuable in a number of applied analyses of VigiBase, ranging from characterizations of reports on drugs for cardiometabolic disease in Sub-Saharan Africa, 15 of well-documented reports, 16 of suspected duplicate reports, 17 and of reports for children. 18 An informal evaluation of vigiPoint against an already published characterization of paediatric ADR reports gave encouraging results: vigiPoint reproduced the findings of the published study and additionally highlighted an over-representation of severe skin reactions (erythema multiforme) 18 that was of interest to domain experts but had not been identified in the original study.
An important next step is to evaluate its use in other domains, to ensure that the chosen analytical approach and design choices generalize to other settings. Design choices that may need re-consideration in other domains include the strength of shrinkage, the confidence interval percentiles for the log-odds ratio to use in screening, and the associated threshold.
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